EP2760442A1 - Compositions contenant de la spermine avec cadaverine, putrescine et/ou spermidine. - Google Patents
Compositions contenant de la spermine avec cadaverine, putrescine et/ou spermidine.Info
- Publication number
- EP2760442A1 EP2760442A1 EP12773094.3A EP12773094A EP2760442A1 EP 2760442 A1 EP2760442 A1 EP 2760442A1 EP 12773094 A EP12773094 A EP 12773094A EP 2760442 A1 EP2760442 A1 EP 2760442A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- food
- spermine
- polyamines
- spermidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/32—Tin compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to novel compositions containing spermine, pharmaceutical compositions containing them, and their uses in the preparation of medicaments for the treatment in a patient of pathologies related to cellular hyperproliferation.
- Polyamines are polycationic aliphatic amines which include putrescine, spermidine, spermine in eukaryotes. Cadaverine, other polyamine, is present only in prokaryotes.
- Polyamines are synthesized from L-arginine or L-methionine. Their pathway of biosynthesis and catabolism is based on a limited number of enzymes.
- ODC Ornithine Decarboxylase
- SpdS Spermidine synthetase
- SpmS spermine synthetase
- S S AT Spermidine / spermine Nl-acetyltransferase
- SSAT allows fine regulation of the intracellular levels of the different polyamines which may be toxic to the cell.
- Spermidine and spermine can also be synthesized from methionine by the action of S-adenosylmethionine decarboxylase (SAMdc).
- SAMdc S-adenosylmethionine decarboxylase
- Logically “active” organic polyamines can be identified in particular according to at least one of the following methods:
- a logically "active" organic polyamine or one of its derivatives must be able to participate in the physiological cellular metabolism of polyamines, or even be able to interfere with the latter or to dysregulate.
- a logically “active” organic polyamine must therefore be able to associate or even be recognized by the transport system or systems intended to internalize it in a living cell.
- the addition of a logically "active" bio-labeled polyamine radiolabeled in the culture medium makes it possible to verify its internalization.
- a logically "active" organic polyamine must be able to suppress the inhibition of cell proliferation caused by the inhibition of the endogenous anabolism of polyamines (eg by ⁇ -DFMO).
- a logically "active" organic polyamine, including synthesis, by dysregulating the natural metabolism of polyamines must be able to modulate the level of cell proliferation.
- the exogenous supply (gastrointestinal tract) of "active" polyamines must suppress the beneficial anti-cancer effects caused by the "active" polyamine deficiency induced by the decrease of endogenous and exogenous sources of "active" polyamines ", This exogenous intake being coupled or not with anticancer drugs.
- Polyamines are essential compounds for cell growth and differentiation.
- the inventors have shown that a diet depleted of polyamines makes it possible to potentiate the effects of inhibitors of ODC on tumor growth (EP 0 703 731 B1).
- the antizyme a protein involved in the degradation of ODC, is capable of modulating the entry or exit of polyamines from the cell according to a mechanism that has not yet been elucidated.
- a mechanism of endocytosis of polyamines mediated by glypican-1 and caveolin-1 has also been reported. More recently, studies have shown the presence of a protein complex consisting of SLC3A2 and LAT proteins capable of excreting putrescine from the cell and returning arginine in exchange.
- Inhibitors of polyamine anabolic enzymes and inhibitors of polyamine transport play an important role in the endogenous synthesis of polyamines by the cells of the body.
- the bacteria of the intestinal flora constitute the second source of endogenous synthesis of polyamines.
- the use of antibiotics targeting these bacteria allows a reduction of this other endogenous source of polyamines.
- Spermine is the final product of the metabolism of polyamines. Its ability to convert spermidine by two different enzymatic pathways (Spermine oxidase or SSAT and polyamine oxidase) gives it an essential role in maintaining the homeostasis of intracellular polyamines. This polyamine is involved in many cellular functions. The prior art shows that spermine has rather deleterious effects on cellular metabolism.
- spermine participates in the metastatic process in prostate cancer where it has been shown that the treatment of HT-29 cells with spermine leads to a decrease in the expression of molecules involved in cell adhesion, promoting thus metastatic invasion (Tsujinaka et al., 2011, Int J Oncology, 38: 305-312).
- the inventors have demonstrated a beneficial effect of spermine on the metabolism of cancer cells which makes it possible to distinguish it from other polyamines participating in cellular homeostasis.
- One of the aims of the invention is to provide compositions for their uses in the treatment of pathologies related to cellular hyperproliferation, in particular in the treatment of cancer.
- Another object of the invention is to provide novel compositions spermine enriched more effective than the compositions described in the prior art in the context of the treatment of pathologies related to cellular hyperproliferation, particularly in the treatment of cancer.
- Another object of the invention is to propose compositions that can be administered to patients together with an anti-cancer treatment.
- the present invention relates to compositions comprising a mixture of cadaverine, putrescine and spermidine at a concentration ranging from 0.3 to 0.6 nmol per gram of composition, said composition also comprising spermine at a concentration ranging from 150 to 17000 nmol by gram of composition.
- spermine represents from 99.60% to 100% of the logically active organic polyamines of the compositions of the present invention.
- the distribution of the logically active organic polyamines of the compositions of the present invention is very different from that of foods constituting a "medium" food ration.
- compositions comprising on the one hand an impoverished mixture cadaverine, putrescine and spermidine and spermine at a concentration higher than that provided by a standard food diet.
- compositions of the present invention may be ingested by a patient who is a mammal.
- mammal means a human being or an animal, said animal may be a pet or a farm animal.
- compositions of the invention have an efficacy that may depend on the stage of the anticancer treatment followed by the patient. This efficiency can be optimum when the compositions are used as the sole or the main exogenous source of polyamines.
- cadaverine, putrescine and spermidine intake should be as low as possible.
- the object of the invention is that the rate of spermine ingested by the patient is much higher than the levels of the other three polyamines. This concentration difference between the spermine and the cadaverine mixture, putrescine and spermidine must be maintained either by the compositions of the invention alone or by the compositions of the invention associated with foods containing little cadaverine, putrescine and spermidine.
- mixture of cadaverine, putrescine and spermidine is meant the combination of the three natural polyamines corresponding respectively to the formulas NH 2 - (CH 2 ) 5 -NH 2 , NH 2 - (CH 2 ) 4 -NH 2 and NH 2 - (CH 2 ) 3 -NH- (CH 2 ) 4 -NH 2 in a composition potentially containing other excipients.
- spermine is meant the natural polyamine corresponding to the formula
- the concentrations of the various polyamines are expressed in nanomoles (nmol) per gram of composition.
- nano moles, nmoles and nmol are equivalent and can be used interchangeably in the text of this application.
- the polyamines of the present invention have the property of being biologically "active" in that they possess at least one biological activity having an effect on:
- N-methyl-D-aspartate (NMD A) receptors and are involved in neurodegenerative processes (Soulet & Rivest 2003).
- the spermine concentration of the compositions of the invention varies from 150 to 1650 nmoles per gram of composition.
- the spermine concentration of the compositions of the invention varies from 500 to 1100 nmol per gram of composition.
- the spermine concentration of the compositions of the invention varies from 1100 to 1650 nmol per gram of composition.
- the spermine concentration of the compositions of the invention ranges from 1650 to 2500 nmol per gram of composition.
- the concentration of spermine compositions of the invention ranges from 2500 to 5000 nmol per gram of composition.
- the spermine concentration of the compositions of the invention varies from 5,000 to 10,000 nmoles per gram of composition.
- the spermine concentration of the compositions of the invention ranges from 100 to 17000 nmol per gram of composition.
- the putrescine concentration of the compositions of the invention varies from 0.19 to 0.32 nmoles per gram of composition.
- the cadaverine concentration of the compositions of the invention ranges from 0.02 to 0.08 nmol per gram of composition. Even more advantageously, the spermidine concentration of the compositions of the invention ranges from 0.09 to 0.20 nmoles per gram of composition.
- compositions of the invention constitute the sole or the main food source of the patients
- these compositions can be enriched with lipids, proteins, carbohydrates, vitamins, minerals and electrolytes in a quantity allowing the patient not to suffer from malnutrition or deficiencies.
- compositions of the invention contain as a percentage of dry weight relative to the total dry weight: 10% to 35% of lipids, 8% to 30% of proteins, 35% to 80% of carbohydrates, up to 10% of a mixture of vitamins, minerals and electrolytes.
- food source is meant all forms of diet, that is to say all foods that may constitute the diet of a human or animal, a diet consisting of meal replacement, or any other food source that keeps the human or animal alive.
- vitamins and minerals having a defined role in the body.
- the vitamins can be selected from a group consisting of vitamin A, vitamin B1, B6, vitamin B, vitamin C, vitamin D3, vitamin K1, riboflavin, pantothenic acid, niacin, folic acid, biotin, choline, inositol.
- the minerals and electrolytes may be selected from a group consisting of sodium, potassium, calcium, phosphorus, magnesium, iron, zinc, copper, manganese, chlorides, iodine, selenium, chromium, molybdenum.
- the choice of vitamins, minerals and electrolytes should not be restricted by the lists listed above. Those skilled in the art can adapt the proportions of each of these constituents allowing the patient to receive a balanced diet, meeting his daily nutritional needs.
- Polyamines in the body come from three main sources: cell proliferation (physiological and tumoral), diet and intestinal bacteria. In order to control as much as possible the supply of polyamines in the body, it may be necessary to limit not only the exogenous supply via a perfectly controlled diet but also to inhibit the endogenous synthesis of the polyamines by using inhibitors of the enzymes involved in the anabolism of polyamines and / or inhibitors of polyamine transport between the cell and the extracellular medium.
- Specific inhibitor denotes a molecule capable of blocking, totally or partially, directly or indirectly, reversibly or otherwise, the active site of at least one of the enzymes involved in the synthesis of polyamines (ornithine decarboxylase (ODC)).
- spermidine-spermine Nl-acetyltransferase or spermine oxidase in the human body, or animal.
- the role of the inhibitor of polyamine biosynthesis is to stop or significantly reduce the endogenous production of polyamines in the organism treated with the product according to the present invention.
- the joint implementation of an inhibitor of polyamine biosynthesis and dietary intake low in polyamines reduces the amount of bioavailable polyamines in the body.
- compositions of the invention optionally contain an inhibitor of the intracellular synthesis of polyamines in a proportion of at most 15% by weight relative to the total dry weight of the composition.
- the inhibitor of the intracellular synthesis of polyamines of the compositions of the invention is an inhibitor of ornithine decarboxylase, spermidine-spermine Nl-acetyltransferase or spermine oxidase.
- alpha-difluoromethylornithine is a useful compound, well known to those skilled in the art (Fabian et al., 2002, Clin Cancer Res, 8 (10), 3105). 3,117 / Levin et al., 2003, Clin Cancer Res, 9 (3), 981-990 / Meyskens et al., 2008, Cancer Prev Res, 1 (1), 32-38).
- This example should in no way restrict the choice of an inhibitor of the endogenous synthesis of polyamines to this compound alone.
- inhibitors capable of inhibiting ornithine decarboxylase, spermidine-spermine Nl-acetyltransferase or spermine oxidase may be used.
- the amounts of inhibitors will be adapted by the skilled person on the basis of the biological activity data of these compounds and his general knowledge.
- compositions of the present invention are optionally enriched with at least one polyamine transport inhibitor, in a proportion of at most 15% by weight relative to the total dry weight of the composition.
- the polyamine transport inhibitors of the compositions of the present invention are preferably inhibitors capable of acting on the intracellular transport, in particular of putrescine and / or spermidine, but which have no effect on the intracellular transport of spermine.
- antibiotics to limit the intake of polyamines by the bacteria of the intestinal flora.
- compositions of the invention optionally contain at least one antibiotic.
- This antibiotic may belong to the group of intestinal antiseptics, such as Ercefuryl ® .
- This antibiotic can also, in addition to its bacteriostatic or bactericidal effect, have an antiparasitic effect, such as Flagyl ® .
- antibiotics may lead to reduce the intake of certain vitamins, especially those provided by the intestinal flora of the patient. In this case, it may be necessary to supplement the composition in these vitamins so as not to cause vitamin deficiencies in the patient in case of prolonged administration of the composition.
- deficits is meant a lack of nutrients that can alter the physical or mental condition of a human or an animal.
- compositions of the invention may be enriched with vitamins.
- the carbohydrates of the compositions of the invention belong to the group comprising glucose polymers, maltodextrins, sucrose, modified starches, glucose monohydrate, dehydrated glucose syrup, glycerol monostearate and mixtures thereof.
- the proteins of the compositions of the invention belong to the group comprising soluble milk proteins, soy proteins, serum peptides, egg white powder, potassium caseinate, non-phosphorylated peptides, casein peptides, mixed caseinate, soy isolate and mixtures thereof.
- the lipids of the compositions of the invention belong to the group comprising butter oil, peanut oil, medium chain triglycerides, grape seed oil, soy evening primrose oil and mixtures thereof.
- the lipids of the compositions of the invention consist of a mixture of at least one oil of animal origin, at least one vegetable oil and glycerol stearate.
- compositions used according to the present invention In order to control the supply of exogenous sources of polyamines, the compositions used according to the present invention must be able to constitute all or part of the patient's diet. In this sense they must provide an energy ration that can meet the nutritional needs of the patient.
- compositions of the invention constitute the daily food ration of a human being and comprise:
- an inhibitor of the intracellular synthesis of polyamines at a rate of less than 50 g and preferably at a rate of 0.3 to 10 g per day.
- compositions of the invention are a submultiple of a daily food ration of a human being and comprise:
- an inhibitor of the intracellular synthesis of polyamines in a proportion of less than 50 ⁇ g and preferably in a proportion of 1 / x to 10 ⁇ g per day,
- the daily food ration is adapted according to the category and mass of the animal, whether it is a pet or a farm animal.
- the distribution of carbohydrates, lipids and proteins as well as the vitamin, mineral and electrolyte requirements of the daily food ration of an animal are well known to those skilled in the art.
- Concerning the intracellular synthesis inhibitor of polyamines, the dose is adapted according to the mass of the animal and possibly on the basis of data obtained in humans.
- compositions used according to the present invention may constitute the daily food ration or a sub-multiple of a daily dietary ration of an animal and will have to satisfy the daily nutritional requirements of an animal.
- compositions used according to the present invention constitute the daily dietary ration of a mouse and comprise:
- an inhibitor of the intracellular synthesis of polyamines at a rate of less than 300 mg and preferably at a rate of 40 to 200 mg per day.
- compositions used according to the present invention may be a submultiple of a daily food ration of a mouse and include:
- vitamins, minerals and electrolytes in sufficient quantities to partially meet the daily nutritional requirements of an animal, and optionally an inhibitor of the intracellular synthesis of polyamines in a proportion of less than 300 / X mg and preferably in a proportion of 40 / X to 200 / X mg per day,
- X being an integer from 2 to 8 and corresponding to the number of rations to be ingested by the patient to meet his daily nutritional requirements.
- compositions of the invention may be in solid, liquid or semi-liquid form. Their formulation is adapted according to the ability of the patient to absorb an oral diet but also enterally or parenterally.
- compositions of the invention are in a dry form to dissolve extemporaneously in a neutral vehicle.
- compositions of the invention include a neutral vehicle making them ready for use.
- neutral vehicle an aqueous solution for producing a more or less liquid composition, facilitating the ingestion of the latter by the patient.
- the compositions of the invention will have a viscosity range extending from that of water to that of milk drinks for a temperature of 4 ° C to 40 ° C, at normal atmospheric pressure.
- compositions of the invention can be used directly as a medicament.
- drug any substance that when ingested by the patient, provides a benefit in terms of welfare, improvement of biomarkers, regression or remission of pathology.
- compositions of the invention may also be included in the formulation of pharmaceutical preparations.
- compositions of the invention can be used in the preparation of a medicament.
- compositions of the invention may be used as a supplement or a food substitute.
- compositions of the invention may be used as a nutraceutical supplement.
- the metabolism of polyamines plays a key role in cell proliferation. Knowing that a disturbance in the physiology of cell division is almost always harmful, it seems appropriate to analyze the effects of a disruption of the metabolism of polyamines in the context of pathologies involving processes of cellular hyperproliferation, and in particular as part of cancer treatment.
- compositions of the invention can be used in the treatment, in a patient, of pathologies related to cellular hyperproliferation.
- compositions of the invention can be used in the treatment, in a patient, of cancer.
- compositions of the invention may be used in the treatment of pathologies related to cellular hyperproliferation or in the treatment of cancer, said treatment being carried out by administering a unit dose ranging from 6.7 mg to 670 mg of spermine.
- compositions of the invention may serve as a basis for a diet which may comprise several phases during which the exogenous supply of polyamines is:
- totally is meant that the patient's diet is restricted to the compositions of the invention. No food other than the compositions of the invention enter the diet of the patient. During this phase, the control of the polyamine intake is maximal.
- compositions of the invention By “majority”, it is meant the possibility of introducing into the patient's diet a breakfast comprising foods reduced in polyamine content. The rest of the daily food ration is provided by the compositions of the invention.
- Partially means the possibility of introducing into the patient's diet a breakfast and at least one solid meal including reduced polyamine foods. The rest of the daily food ration is provided by the compositions of the invention.
- compositions used according to the present invention are administered to the patient according to the following scheme:
- patient reaction is meant its physiological ability to benefit from a depleted polyamine diet.
- the benefit can be appreciated especially from the regression of the tumor mass.
- the improvement or disappearance of any sign of the disease can be evaluated by a clinical examination, biological examinations or imaging performed in a usual way in the context of cancer. These criteria vary depending on the type of cancer. Three hypotheses are possible:
- the second dose of the composition will contain at most the same level of polyamines as the first dose
- the second dose of the composition will contain at least the same level of polyamines as the first dose, or Physiological condition of the patient has degraded after administration of a first dose of the composition and in this case, the second dose of the composition will contain a polyamine level either higher or lower than that of the first dose.
- the three doses are identical, it amounts to administering a single dose to the patient for a period determined by the practitioner.
- the first period of time varies from 7 to 14 days, in particular 7 days.
- the second period of time varies from 14 to 21 days, in particular 14 days.
- the third period of time varies from 28 to 63 days, in particular 63 days.
- the first, second, and third time periods constitute a complete cycle of patient treatment.
- the administration of the compositions of the invention may take place for one, two or more cycles. The renewal of these cycles is left to the discretion of the practitioner.
- the first dose of polyamines varies from 6.7 mg to 5.3 g of spermine / day
- the second dose of polyamines varies from 6.7 mg to 5.3 g of spermine / day, and
- the third dose of polyamines ranges from 6.7 mg to 5.3 g of spermine / day.
- These doses correspond to the doses of polyamines provided by 1 to 8 rations of a diet depleted of cadaverine, putrescine and spermidine and spermine-enriched dose 33.4 mg / kg of food at the dose 3340 mg / kg of food .
- compositions of the present invention provide at least the same daily amount of spermine and up to 800 times more spermine than an average food ration.
- compositions comprising:
- spermine at a concentration ranging from 150 to 17000 nmol per gram of composition
- the total amount of logically active organic polyamines ingested per day by the patient does not exceed 11334 nanomoles per kcal of ingested composition, in particular 5000 nanomoles per kcal of composition ingested, in particular 1000 nanomoles per kcal of ingested composition, in particular 100 nanomoles per kcal of ingested composition.
- the compositions of the invention may be used as a second therapeutic agent.
- compositions of the invention may be administered to the patient before and / or during and / or after the anti-cancer treatment.
- the present invention also relates to a combination of a composition comprising:
- spermine at a concentration ranging from 150 to 17000 nmol per gram of composition
- the total amount of bio logically active polyamines ingested per day by the patient not exceeding 11334 nanomoles per kcal of ingested composition , in particular 5000 nanomoles per kcal of ingested composition, in particular 1000 nanomoles per kcal of ingested composition, in particular 100 nanomoles per kcal of ingested composition.
- This figure represents the variations in tumor volume (in cm 3 , indicated on the ordinate) as a function of the number of days (indicated on the abscissa) elapsed after the grafting of said tumor in male C57BL / 6 mice.
- the mice are grafted with a solid tumor of Lewis lung carcinoma cells.
- Figure 1-A Four groups of five mice are fed with different diets 6 days after the transplant took place. The start of treatment is indicated by the arrow on the graph.
- the curve marked by black circles represents the mice fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food).
- the curve represented by empty circles represents the mice fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food), and a drinking water containing neomycin (2 mg / ml).
- the curve represented by black squares represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food).
- the curve represented by empty squares represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and a drinking water containing neomycin (2 mg / ml).
- Figure 1-B Six groups of five mice are fed with different diets 6 days after the transplant took place. The start of treatment is indicated by the arrow on the graph.
- the curve marked by black circles represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (33.4 mg / kg of food (165 nmole / g of food).
- the curve represented by black squares represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food) and enriched in spermine (334 mg / kg of food 1650 nmol / g of food).
- the curve represented by empty squares represents the mice fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (334 mg / kg of food 1650 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- the curve represented by black diamonds represents the mice fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food 0.350 nmol / g of food) and enriched with spermine (3340 mg / kg of food or 16500 nmol / g of food).
- the curve represented by empty squares represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (3340 mg / kg of food 16500 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- This figure represents the percentage of pulmonary metastatic invasion (on the ordinate) of male C57BL / 6 mice, as a function of the diet (on the abscissa) given to the mice that had received a solid tumor transplant of Lewis carcinoma cells.
- the percentage of pulmonary metastatic invasion is measured 19 days after the transplant took place.
- mice Ten groups of mice are fed different diets.
- the first group (represented by a black column) is fed with a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmole / g of food).
- the average value of pulmonary metastatic invasion of mice in this group is 27%.
- the second group (represented by a white column) is fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food), and a drinking water containing neomycin (2 mg / ml).
- the average value of pulmonary metastatic invasion of the mice of this group is 11%.
- the third group (represented by a column containing discontinuous vertical lines) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food).
- the average value of pulmonary metastatic invasion of the mice of this group is 6%.
- the fourth group (represented by a column containing horizontal discontinuous lines) is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg feed or 0.350 nmole / g feed), and a drinking water containing neomycin (2 mg / ml).
- the average value of pulmonary metastatic invasion of the mice of this group is 7%.
- the fifth group (represented by a column containing vertical continuous lines) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched with spermine (33 , 4 mg / kg of food or 165 nmol / g of food).
- the average value of pulmonary metastatic invasion of the mice of this group is 13%.
- the sixth group (represented by a column containing horizontal continuous lines) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (33, 4 mg / kg of food (165 nmole / g of food) and drinking water containing neomycin (2 mg / ml).
- the average value of pulmonary metastatic invasion of the mice of this group is 4%.
- the seventh group (represented by a column containing continuous lines pointing to the left) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (334 mg / kg of food or 1650 nmol / g of food).
- the average value of pulmonary metastatic invasion of the mice of this group is 7%.
- the eighth group (represented by a column containing continuous lines pointing to the right) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine ( 334 mg / kg of food (1650 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- the average value of pulmonary metastatic invasion of the mice of this group is 7%.
- the ninth group (represented by a column containing small dots) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (3340 mg / kg of food is 16500 nmol / g of food).
- the average value of pulmonary metastatic invasion of the mice of this group is 5%.
- the tenth group (represented by a column containing large dots) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (3340 mg / kg of food (16500 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- the average value of pulmonary metastatic invasion of the mice of this group is 1%.
- Figure 3 Evolution of tumor levels of polyamines
- This figure represents the tumor levels of putrescine, spermidine and spermine (on the ordinate) of male C57BL / 6 mice, as a function of the diet (on the abscissa) given to the mice which have received the transplant of a solid tumor of Lewis carcinoma cells. .
- the tumor levels of putrescine, spermidine and spermine are measured 19 days after the graft has taken place.
- FIG. 3A Four groups of five mice are fed different diets 6 days after the transplant took place.
- the black column represents the mice fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food).
- the white column represents the mice fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food), and a drinking water containing neomycin (2 mg / ml).
- the column containing vertical discontinuous lines represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food).
- the column containing horizontal discontinuous lines represents mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and a drinking water containing neomycin (2 mg / ml).
- FIG. 3B Six groups of five mice are fed with different diets 6 days after the transplant took place.
- the column containing vertical continuous lines represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (33.4 mg / kg of food (165 nmole / g of food).
- the column containing horizontal continuous lines represents the mice fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (33.4 mg / kg d 'food 165 nmole / g of food) and drinking water containing neomycin (2 mg / ml).
- the column containing continuous lines pointing to the left represents the mice fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food) and enriched in spermine (334 mg / kg of food is 1650 nmol / g of food).
- the column containing straight lines pointing to the right represents the mice fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (334 mg / kg d feed (1650 nmol / g food) and drinking water containing neomycin (2 mg / ml).
- the column containing small dots represents the mice fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food) and enriched in spermine (3340 mg / kg of food either 16500 nmol / g of food).
- the column containing large dots represents the mice fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (3340 mg / kg of food or 16500 nmol / g food) and drinking water containing neomycin (2 mg / ml).
- This figure represents the mass of the spleen (ordinate) of male C57BL / 6 mice, as a function of the diet (in abscissas) given to the mice which have received or not the transplant of a solid tumor of Lewis carcinoma cells.
- the mass of the spleen is measured 19 days after the transplant took place.
- mice transplanted with a solid tumor of Lewis carcinoma cells are fed different diets.
- An eleventh group of mice not receiving a graft and placed under a diet containing a normal level of polyamines makes it possible to establish an average reference value of the splenic mass in the mice used in this study.
- the first group (represented by a black column) is fed with a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food).
- the average value of the splenic mass of mice in this group is 171 mg.
- the second group (represented by a white column) is fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food), and a drinking water containing neomycin (2 mg / ml).
- the mean value of the splenic mass of mice in this group is 151 mg.
- the third group (represented by a column containing discontinuous vertical lines) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food).
- the mean value of the splenic mass of mice in this group is 88 mg.
- the fourth group (represented by a column containing horizontal discontinuous lines) is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg feed or 0.350 nmole / g feed), and a drinking water containing neomycin (2 mg / ml).
- the mean value of the splenic mass of mice in this group is 63 mg.
- the fifth group (represented by a column containing vertical continuous lines) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched with spermine (33 , 4 mg / kg of food or 165 nmol / g of food).
- the mean value of the splenic mass of mice in this group is 93 mg.
- the sixth group (represented by a column containing horizontal continuous lines) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (33, 4 mg / kg of food (165 nmole / g of food) and drinking water containing neomycin (2 mg / ml).
- the mean value of the splenic mass of mice in this group is 75 mg.
- the seventh group (represented by a column containing continuous lines pointing to the left) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (334 mg / kg of food or 1650 nmol / g of food).
- the mean value of the splenic mass of mice in this group is 98 mg.
- the eighth group (represented by a column containing straight lines pointing to the right) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg diet or 0.350 nmol / g feed), spermine-enriched (334 mg / kg diet or 1650 nmol / g food) and drinking water containing neomycin (2 mg / ml).
- the average value of the splenic mass of mice in this group is 100 mg.
- the ninth group (represented by a column containing small dots) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (3340 mg / kg of food is 16500 nmol / g of food).
- the mean value of the splenic mass of mice in this group is 81 mg.
- the tenth group (represented by a column containing large dots) is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (3340 mg / kg of food (16500 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- the mean value of the splenic mass of mice in this group is 42 mg.
- the eleventh group (represented by a gray column), corresponding to the mice not receiving a graft, is fed with a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food) .
- the mean value of the splenic mass of mice in this group is 61 mg.
- mice Male C57BL / 6 mice, 9 weeks old and weighing 20g (January breeding, Genest St Isle, France) are acclimated 1 week before the start of the study. Animal handling is carried out in accordance with the ethical guidelines for experimentation and according to the recommendations of the European Association for Biomedical Research. The animals are enclosed at 5 individuals per cage under standardized conditions (21 ⁇ 1 ° C, 60% relative humidity, cycles of 12 hours of light, 12 hours of darkness), and have access to food and feed. water ad libitum. 1.2 - Tumor model
- Lewis lung carcinoma cells (3LL) were obtained from the ECACC (European Collection of Cell Cultures) and grafted by intramuscular injection into the hind paws of male C57BL / 6 mice according to the method previously described (Hergueux J. et al. al., Cell BioL Exp., 1983, 51 (4), 181-191) to produce tumor cells. After 20 days, the tumor cells are collected and dispersed in PBS, counted and diluted to reach 0.5 ⁇ 10 6 cells / 100 ⁇ l, before being grafted into the right hind paw of the mice. The grafted mice are randomly distributed in the cages in groups of 5 individuals.
- the animals are sacrificed 19 days after the tumor cell transplant.
- the depleted diet of cadaverine, putrescine and spermidine is marketed under the brand CASTASE TM by Nutrialys (Saint-Grégoire, France).
- This polyamine-depleted food contains less than 51 ⁇ g of polyamines / kg of food.
- the rodent feed containing a normal level of polyamines corresponds to a standard commercial feed (UAR, standard feed mill).
- the products are distributed to the animals according to their profile and their nutritional needs.
- a mouse consumes about 2 grams per day of feeding.
- the treatment is set up 6 days after the transplant, when the tumor is palpable and is administered 7 days out of 7 and includes the ad libitum intake of the normal diet or test solutions as well as the drinking water.
- mice C57BL / 6 mouse
- tumor model Lewis carcinoma
- the growth of the tumor is quantified at 6, 8, 11, 14 and 18 days after the graft has taken place by measuring the volume of the tumor, according to the method previously described (Moulinoux et al., Int J. Cancer, 1984, 34 (2), 277-281).
- mice are divided into ten groups and different diets are administered to each group.
- the first group is fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food).
- the second group is fed a diet containing a normal level of polyamines and a drinking water containing neomycin (2 mg / ml).
- the third group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food).
- the fourth group is fed a diet depleted of cadaverine, putrescine and spermidine, and a drinking water containing neomycin (2 mg / ml).
- the fifth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (33.4 mg / kg of food or 165 nmol / g of food).
- the sixth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (33.4 mg / kg of food or 165 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- the seventh group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (334 mg / kg of food or 1650 nmol / g feed).
- the eighth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (334 mg / kg of food or 1650 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- the ninth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (3340 mg / kg of food or 16500 nmol / g feed).
- the tenth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (3340 mg / kg of food or 16500 nmol / g of food) and drinking water containing neomycin (2 mg / ml).
- Neomycin is diluted in drinking water (0.2% w / v) whether the animals are fed with a diet in a solid form of kibble, or with a diet in a liquid or semi-liquid form.
- Neomycin has no effect on the evolution of tumor volume when administered in drinking water on the basis of a diet containing a normal level of polyamines.
- the depleted diet of cadaverine, putrescine and spermidine causes a 20% decrease in tumor growth on day 19. This decrease is 35% when neomycin is added to this depleted cadaverine, putrescine and spermidine regimen ( Figure 1-A).
- Neomycin supplemented with a diet containing a normal level of polyamines causes a 60% decrease in metastatic invasion compared to that seen in mice that did not receive this antibiotic.
- the cadaverine depleted diet, putrescine and spermidine caused a 77% decrease in metastatic invasion compared to that observed in mice fed a diet containing a normal level of polyamines.
- the addition of neomycin to a diet depleted of cadaverine, putrescine and spermidine has no additional benefit.
- the level of polyamines is measured in the tumor formed at the site of inoculation of Lewis carcinoma cells.
- the tumor was washed and the cells that compose it are dispersed using a Polytron ® homogenizer in the presence of 0.2 M perchloric acid. After incubation for at least 16 h at 4 ° C, the cells are centrifuged for 15 minutes at 3500 rpm at 4 ° C. The supernatant which contains the polyamines is taken and used for the determination of the polyamines.
- the polyamines are assayed according to the method previously described (Seiler N et al., 1996, Cancer Research, 56, 5624-5630). The three main polyamines present in mammals (putrescine, spermidine and spermine) were measured for the ten groups of mice each receiving a distinct diet. The results are shown in Figure 3.
- Neomycin causes a 17% decrease in putrescine, a 7% increase in spermine level and has no effect on spermidine levels based on a normal diet. In contrast, neomycin causes a 17% increase in putrescine level, a 24% increase in spermidine level and a 5% decrease in spermine levels based on a depleted cadaverine, putrescine and spermidine regimen. .
- the depleted cadaverine, putrescine and spermidine regimen induced an increase of 17% and 24%, respectively, in tumor levels of putrescine and spermidine.
- This diet has no effect on the tumor rate of spermine.
- Spermine supplementation of the cadaverine depleted diet, putrescine and spermidine induces variations in tumor levels of putrescine, spermidine and spermine.
- the tumoral rate of putrescine increases by 17%
- the tumoral rate of spermidine increases by 25%
- the tumoral rate of spermine decreased by 6% compared to the tumor levels of these two polyamines in mice fed a diet containing a normal level of polyamines.
- the tumor rate of spermidine increases by 32% and the tumoral rate of spermine increases by 12%) relative to the tumor levels of these substances.
- the spleen is taken from the mice and weighed using a precision balance.
- mice each having a distinct diet, as previously described, an eleventh group of animals was included for this study. These are male C57BL / 6 mice with the same basic physiological characteristics as the mice in the other 10 groups but who did not undergo a Lewis carcinoma cell transplant. The mice of this eleventh group were fed with the diet containing a normal level of polyamines. The splenic mass of these healthy mice (61 mg) serves as a reference for an animal with no sign of inflammation.
- mice which have been transplanted with Lewis carcinoma cells and placed under a diet containing a normal level of polyamines have a splenic mass. three times higher (171 mg) than healthy mice fed the same diet.
- Neomycin causes a decrease in splenic mass irrespective of the nature of the diet ingested by the mice.
- the cadaverine depleted diet, putrescine and spermidine induced a decrease of about 50% of the splenic mass in these mice compared to the transplanted mice that received a diet containing a normal level of polyamines.
- spermine enrichment of the cadaverine depleted diet, putrescine and spermidine has no additional effect in terms of decreased splenic mass and therefore inflammation in these animals carrying a tumor.
- Neomycin combined with an enrichment of the cadaverine depleted diet, putrescine and spermidine by 3340 mg spermine / kg feed (ie 16500 nmol / g feed) leads to a decrease in splenic mass below that of healthy animals.
- mice Male C57BL / 6 mice, 9 weeks old and weighing 20g (January breeding, Genest St Isle, France) are acclimated 1 week before the start of the study. Animal handling is carried out in accordance with the ethical guidelines for experimentation and according to the recommendations of the European Association for Biomedical Research.
- the animals are enclosed at 5 individuals per cage under standardized conditions (21 ⁇ 1 ° C, 60% relative humidity, cycles of 12 hours of light, 12 hours of darkness), and have access to food and feed. water ad libitum.
- Lewis lung carcinoma cells (3LL) were obtained from ECACC (European Collection of Cell Cultures) and grafted by injection intramuscularly in the hind legs of male C57BL / 6 mice according to the method previously described (Hergueux J. et al., Exp Cell BioL, 1983, 51 (4), 181-191) to produce tumor cells. After 20 days, the tumor cells are collected and dispersed in PBS, counted and diluted to reach 0.5 ⁇ 10 6 cells / 100 ⁇ l, before being grafted into the right hind paw of the mice. The grafted mice are randomly distributed in the cages in groups of 5 individuals.
- the tumor becomes palpable a few days after the transplant has taken place.
- the animals are sacrificed 19 days after the tumor cell transplant. 2 - Food
- the depleted diet of cadaverine, putrescine and spermidine is marketed under the brand CASTASE TM by Nutrialys (Saint-Grégoire, France).
- This polyamine-depleted food contains less than 51 ⁇ g of polyamines / kg of food.
- the rodent feed containing a normal level of polyamines corresponds to a standard commercial feed (UAR, standard feed mill).
- the products are distributed to the animals according to their profile and their nutritional needs.
- a mouse consumes about 2 grams per day of feeding.
- the treatment is set up 6 days after the transplant, when the tumor is palpable and is administered 7 days out of 7 and includes the ad libitum intake of the normal diet or test solutions as well as the drinking water.
- mice C57BL / 6 mouse
- tumor model Lewis carcinoma
- the growth of the tumor is quantified at 6, 8, 11, 14 and 18 days after the graft has taken place by measuring the volume of the tumor, according to the method previously described (Moulinoux et al., Int J. Cancer, 1984, 34 (2), 277-281).
- mice are divided into fifteen groups and different diets are administered to each group.
- the first group is fed a diet containing a normal level of polyamines (125 mg / kg of food or 861 nmol / g of food).
- the second group was fed a diet containing normal levels of polyamines and cyclophosphamide dose of 9 mg.kg "1. Week" 1.
- the third group is fed a diet containing a normal level of polyamines and a dose of cyclophosphamide of 90 mg.kg- 1 week -1 .
- the fourth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food).
- the fifth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food) and a dose of cyclophosphamide 9 mg.kg "1 .week " 1 .
- the sixth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food) and a cyclophosphamide dose of 90 mg.kg "1 .week " 1 .
- the seventh group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (33.4 mg / kg of food or 165 nmol / g of food).
- the eighth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (334 mg / kg of food or 1650 nmol / g of 'food).
- the ninth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), and enriched in spermine (3340 mg / kg of food or 16500 nmol / g feed).
- the tenth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (33.4 mg / kg of food or 165 nmol / g of food) and a dose of cyclophosphamide of 9 mg.kg- 1 week -1 .
- the eleventh group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (334 mg / kg of food or 1650 nmol / g of food) and a dose of cyclophosphamide 9 mg.kg "1. week" 1.
- the twelfth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (3340 mg / kg of feed is 16500 nmol / g of food) and a dose of cyclophosphamide 9 mg.kg "1. week" 1.
- the thirteenth group is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (33.4 mg / kg of food or 165 nmol / g of food) and cyclophosphamide dose of 90 mg.kg "1. week" 1.
- the fourth group is fed a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (334 mg / kg of food or 1650 nmol / g of feed) and a dose of cyclophosphamide of 90 mg.kg- 1 week -1 .
- the fifteenth group is fed with a diet depleted of cadaverine, putrescine and spermidine (51 ⁇ g / kg of food or 0.350 nmol / g of food), enriched in spermine (3340 mg / kg of food or 16500 nmol / g of feed) and a dose of cyclophosphamide of 90 mg.kg- 1 week -1 .
- Cyclophosphamide (Endoxan) administered at 90 mg.kg -1 week -1 has a significant antiproliferative effect irrespective of the diet provided.
- the percentage inhibition is of the order of 80 to 95%.
- a low dose of cyclophosphamide 9 mg.kg "1.
- Week” 1 associated with a depleted diet cadaverine, putrescine and spermidine increases the antitumor efficacy of 25% compared to a diet containing a ratio normal polyamine (125 mg / kg feed, 861 nmol / g feed) combined with 9 mg.kg- 1 week- 1 cyclophosphamide.
- This depleted diet cadaverine, putrescine and spermidine enriched spermine increases dose-dependently the antitumor effect of cyclophosphamide to 9 mg.kg "1. Week” 1 5 to 30%, depending on the doses of spermine .
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1158774A FR2980709B1 (fr) | 2011-09-29 | 2011-09-29 | Compositions contenant de la spermine et compositions pharmaceutiques les contenant |
PCT/FR2012/052162 WO2013045826A1 (fr) | 2011-09-29 | 2012-09-26 | Compositions contenant de la spermine avec cadaverine, putrescine et/ou spermidine. |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2760442A1 true EP2760442A1 (fr) | 2014-08-06 |
Family
ID=47023027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12773094.3A Withdrawn EP2760442A1 (fr) | 2011-09-29 | 2012-09-26 | Compositions contenant de la spermine avec cadaverine, putrescine et/ou spermidine. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2760442A1 (fr) |
FR (1) | FR2980709B1 (fr) |
WO (1) | WO2013045826A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018059216A1 (fr) | 2016-09-29 | 2018-04-05 | 广州君赫生物科技有限公司 | Composés réduisant l'activité de saicar synthase, et applications |
US11517541B2 (en) | 2017-04-20 | 2022-12-06 | Geneheal Biotechnology Co., Ltd. | Applications of spermidine and its derivatives |
EP3613416B1 (fr) | 2017-04-20 | 2021-12-15 | Geneheal Biotechnology Co., Ltd. | Application de la spermine et de ses dérivés dans la préparation d'un médicament anticancéreux |
EP3830300A1 (fr) | 2018-07-31 | 2021-06-09 | Debreceni Egyetem | Traitement et diagnostic du cancer du sein |
CN110214869A (zh) * | 2019-07-03 | 2019-09-10 | 四川农业大学 | 一种促进公猪睾丸细胞增殖发育的复合添加剂及制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
WO1997011691A1 (fr) * | 1995-09-29 | 1997-04-03 | Children's Medical Center Corporation | Traitement du cancer de la prostate chez l'homme |
US7425579B2 (en) | 1998-04-21 | 2008-09-16 | Universite Laval | Methods for inhibiting activity of polyamine transporters |
AU8657398A (en) | 1998-07-30 | 2000-02-21 | Picower Institute For Medical Research, The | Immunotherapeutic anti-cancer pharmaceutical compositions |
JP2004506683A (ja) | 2000-08-24 | 2004-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | α−ジフルオロメチルオルニチン(DFMO)は、ヒト前立腺におけるポリアミンレベルを抑制する |
FR2858231B1 (fr) * | 2003-07-31 | 2006-02-10 | Univ Rennes | Utilisation nouvelle d'une composition alimentaire a usage humain pauvre en polyamines pour la realisation d'un aliment therapeutique |
FR2896127B1 (fr) * | 2006-01-17 | 2008-04-11 | Univ Rennes I Etablissement Pu | Utilisation nouvelle d'une composition alimentaire a usage humain ou veterinaire pauvre en polyamines pour la realisation d'un aliment therapeutique |
JP4935173B2 (ja) * | 2006-04-26 | 2012-05-23 | 東洋紡績株式会社 | 植物からのポリアミン組成物の調製方法 |
KR20090027896A (ko) * | 2007-09-13 | 2009-03-18 | 한국과학기술연구원 | 아민 카르바밀레이티드 유도체화와액체크로마토그래피/전기분무-이중질량분석기를 이용한인체의 뇨 또는 혈청에서의 폴리아민 검출 방법 |
US9212131B2 (en) | 2009-06-19 | 2015-12-15 | University Of Central Florida Research Foundation, Inc. | Polyamine transport inhibitors as novel therapeutics |
US20110236512A1 (en) * | 2009-09-28 | 2011-09-29 | Toyo Boseki Kabushiki Kaisha | Stress-reducing agent including plant-derived polyamine-containing extract serving as active component |
-
2011
- 2011-09-29 FR FR1158774A patent/FR2980709B1/fr not_active Expired - Fee Related
-
2012
- 2012-09-26 WO PCT/FR2012/052162 patent/WO2013045826A1/fr active Application Filing
- 2012-09-26 EP EP12773094.3A patent/EP2760442A1/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO2013045826A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013045826A1 (fr) | 2013-04-04 |
FR2980709B1 (fr) | 2013-10-25 |
FR2980709A1 (fr) | 2013-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080317886A1 (en) | Compositions for Preventing and Reducing Delayed Onset Muscle Soreness | |
EP2760442A1 (fr) | Compositions contenant de la spermine avec cadaverine, putrescine et/ou spermidine. | |
EP0703731B1 (fr) | Composition a usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications therapeutiques | |
FR2997302A1 (fr) | Prevention et traitement des deficits en pyruvate deshydrogenase | |
WO2013104871A1 (fr) | Compositions contenant de l'agmatine et leurs utilisations dans la preparation de medicaments ou de substances nutraceutiques | |
EP1302115A1 (fr) | Utilisation de cystathionine | |
EP0655244B1 (fr) | Composition à base d'acides aminés pour le traitement d'infections | |
EP2663286B1 (fr) | Action preventive de la citrulline sur le developpement spontane des tumeurs | |
EP2440195B1 (fr) | Utilisation d'alkylglycerols pour la preparation de medicaments | |
EP1973425B1 (fr) | Utilisation nouvelle d'une composition alimentaire a usage humain ou veterinaire pauvre en polyamines pour la realisation d'un aliment therapeutique | |
EP2452577B1 (fr) | Solution aqueuse de phytine et utilisation de ladite solution pour la préparation d'un complément alimentaire liquide ou d'une composition cosmétique | |
EP0703732B1 (fr) | Composition a usage alimentaire et/ou pharmaceutique pauvre en polyamines | |
FR2619313A1 (fr) | Nouvelles compositions d'elements mineraux et/ou oligoelements et leur procede de preparation | |
CA2847001A1 (fr) | Utilisation de compositions a faible teneur en polyamines dans la prevention ou le traitement des effets indesirables lies a un traitement anti-cancereux | |
BE1028307B9 (fr) | Aliments complémentaires pour animaux comprenant GABA, 5-HTP et cofacteurs ciblés | |
WO2022074154A1 (fr) | O-acétylsérine pour son utilisation dans la prévention et le traitement de l'intolérance au glucose et les maladies associées | |
Remesar Betlloch et al. | Dietary energy partition: the central role of glucose | |
EP2645882A1 (fr) | Utilisation d'une composition alimentaire dans le traitement et/ou la prévention des douleurs neuropathiques induites par un agent anticancéreux | |
EP3946405A1 (fr) | Composition de desmodium et de chrome trivalent et utilisation à visee oculaire | |
TW200534798A (en) | An energy addition type amino acid composition or an amino acid solution containing glutamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140328 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UNIVERSITE DE RENNES 1 Owner name: NUTRIALYS MEDICAL NUTRITION SA |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150721 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151201 |